- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Sean McGowan on What’s in Store for Biosimilars in 2021 and Beyond
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, discusses how 2020 has affected biosimilar development and his predictions for the industry going forward.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, recently appeared during a series of interviews on MJH Life Sciences™’ Medical World News about the challenges of bringing a biosimilar to market, how to ensure biosimilar competition in the future, and what to keep an eye on as the market grows over time. Today, we are bringing you the first part of that discussion, which focuses on McGowan’s thoughts on how 2020 has shaped biosimilar progress and his main predictions for the future of the biosimilars industry.
To watch the full first part of this interview, click here.
To watch part 2 of this interview, click here.
To watch part 3 of this interview, click here.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.
